Meta-analyses of treatment standards for pancreatic cancer

• DOI: 10.3892/mco.2015.716
• Publication Date: 2015-12-18T13:33:44Z
• Authors: JUN GONG; RICHARD TULI; ARVIND SHINDE; ANDREW E. HENDIFAR
• Keywords: Neoadjuvant Therapy; Adjuvant Therapy

Pancreatic cancer is the most lethal common with an estimated 5-year survival rate of 6-7% (across all stages). The only potential curative therapy surgical resection in those localized disease. Adjuvant (postoperative) confers a advantage over postoperative observation alone. Neoadjuvant (preoperative) offers to downstage initially unresectable tumors for resection, sterilize margins and decrease locoregional recurrence, identify subset patients aggressive disease whom surgery will not be beneficial. Induction chemotherapy followed by consolidation chemoradiation another recommended approach locally advanced For who cannot downstaged, tolerate surgery, or were diagnosed metastatic disease, treatment remains palliative being critical component this approach. Recently, intensive combination has been shown improve rates comparison gemcitabine alone past few decades have afforded accumulation high-level evidence regarding neoadjuvant, adjuvant therapies pancreatic cancer. There are numerous reviews discussing recent retrospective studies, prospective studies randomized controlled trials each these areas. However, optimal strategies across stages that focus on highest levels hierarchical evidence, such as meta-analyses, limited. discussion novel therapeutics beyond scope review. extensive current collection meta-analyses first-line systemic options date accumulated.